FDA Shocks Sarepta, Ordering AdComm for DMD Gene Therapy in Sudden Change of Heart

Two weeks after saying the FDA would assess its gene therapy without an advisory committee meeting, Sarepta has revealed the agency will now convene experts to dig into the data on its Duchenne muscular dystrophy submission.